CITIUS ONCOLOGY INC

For the period ended Sep 30, 2024. Filed Dec 27, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Dec 27, 2024

CTOR$0.55+7.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

SEPTEMBER 30, 2024 AND 2023

	2024	2023
Current Assets:
Cash and cash equivalents	$112	$—
Inventory	8,268,766	—
Prepaid expenses	2,700,000	7,734,895
Total Current Assets	10,968,878	7,734,895
Other Assets:
In-process research and development	73,400,000	40,000,000
Total Other Assets	73,400,000	40,000,000
Total Assets	$84,368,878	$47,734,895
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$3,711,622	$1,289,045
License payable	28,400,000	—
Accrued expenses	—	259,071
Due to related party	588,806	19,499,119
Total Current Liabilities	32,700,429	21,047,235
Deferred tax liability	1,728,000	1,152,000
Note payable to related party	3,800,111	—
Total Liabilities	38,228,540	22,199,235
Stockholders’ Equity:
Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding	—	—
Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively	7,155	6,750
Additional paid-in capital	85,411,771	43,658,750
Accumulated deficit	(39,278,587)	(18,129,840)
Total Stockholders’ Equity	46,140,339	25,535,660
Total Liabilities and Stockholders’ Equity	$84,368,878	$47,734,895

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.